Open AccessLoss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC
Author(s) -
Sebastian Michels,
Matthias Scheffler,
Svenja Wagener,
Dennis Plenker,
Andreas H. Scheel,
Lucia Nogová,
Anne M. Schultheis,
Rieke Fischer,
Diana S.Y. Abdulla,
Richard Riedel,
Anne Bunck,
Carsten Kobe,
Wolfgang W. Baus,
Sabine MerkelbachBruse,
Martin L. Sos,
Reinhard Büttner,
Jürgen Wolf
Publication year - 2018
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.18.00121
Subject(s) - crizotinib , ros1 , medicine , mutation , oncology , chemotherapy , resistance (ecology) , lung cancer , genetics , adenocarcinoma , cancer , biology , gene , malignant pleural effusion , ecology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom